Compare Abeona Therapeutics Inc (ABEO) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs State Street PDR S&P Retail ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while State Street PDR S&P Retail ETF trades at $89.79. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | XRT | |
|---|---|---|
Market Cap | $424.33M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $7.45 | $92.35 |
52-Week Low | $4.17 | $77.28 |
Enterprise Value | $279.23M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
XRT trades at $90.82, up 1.08% with a bullish technical signal supported by moving averages. The ETF shows neutral oscillators like RSI at 57.83, while ADX indicates a strong trend. Support lies at $90 and resistance at $91. Recent retail sales growth and positive economic data provide a favorable backdrop, though sentiment is mixed amid inflation concerns.
Outlook is cautiously optimistic with retail sector momentum, but risks include consumer sentiment pressures and valuation headwinds. The ETF's diversification offers stability, yet macroeconomic shifts could impact performance. Investors should weigh technical strength against fundamental uncertainties in the retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
